CytoSorbents Corporation reported total revenue of approximately $37.1 million for the fiscal year ended December 31, 2025, marking a 4.1% increase from $35.6 million in 2024. The company's gross profit improved to $26.5 million, resulting in a gross margin of 71.5%, up from 69.9% in the previous year. Despite the revenue growth, CytoSorbents recorded a net loss of $8.2 million, a significant reduction from the $20.7 million loss reported in 2024. This improvement in loss was attributed to increased sales and enhanced gross margins, alongside a strategic workforce and cost reduction plan initiated in late 2025.
The company has made notable strides in its operational strategy, including a proactive reorganization of its German commercial team to address declining sales in that market. CytoSorbents also highlighted the successful completion of the STAR-T clinical trial, which demonstrated the effectiveness of its DrugSorb-ATR device in reducing serious perioperative bleeding in patients on blood thinners. The company plans to file a new De Novo application for DrugSorb-ATR with the FDA, following an earlier denial that cited the need for additional information but confirmed no safety concerns.
In terms of market presence, CytoSorbents has expanded its distribution network, with its lead product, CytoSorb®, now available in over 70 countries. The company has also established subsidiaries in India and Dubai to enhance its international reach. As of December 31, 2025, CytoSorbents had approximately 129 employees and reported a cash balance of $7.8 million, raising concerns about its ability to sustain operations without additional funding. The company is actively exploring various financing options, including equity offerings and debt financing, to support its growth initiatives.
The financial outlook for CytoSorbents remains cautious, with management emphasizing the need to achieve cash-flow profitability by the second half of 2026. The company is also focused on mitigating the impact of inflation on its operations, which has led to increased labor and raw material costs. CytoSorbents continues to engage with regulatory bodies to secure necessary approvals for its products, which are critical for its future revenue generation and market competitiveness.
About Cytosorbents Corp
CytoSorbents Corporation specializes in blood purification technologies for critical care, cardiac surgery, and organ transplantation. Its flagship product, CytoSorb, removes inflammatory mediators, toxins, and blood thinners from blood using porous polymer beads. The company develops and markets extracorporeal cartridges and devices globally, targeting high-risk patients with conditions like sepsis, COVID-19, organ failure, and bleeding risks, with a focus on improving clinical outcomes and reducing healthcare costs.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.